Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes get everyone up to speed at the weekend and maybe a BLOCKBUSTER RNS AT 7am Monday morning !! Or Intra day RNS to coincide with NASDAQ
Don't understand what's happening to the blood top.line data from Brazilian CV trial. We were told excited as smell and taste returned and full data would be available within about a couple of weeks from Dr W interview
Maybe to coincide with something in the coming week? More relevant for now than a month ago.. Or to remind people that they exist.
The interview was recorded on 1st February 2021 !!! So how come it’s only just being aired now at the end of February ?
No news on Accustem !!!
Possible phase 2 trials in the US is welcoming news
I liked the drone company too.
Nothing new. Back to a £1 then.
Given it was aired on Bloomberg stateside last night one has to assume no new news or would have been all over Stockwits like a rash!
I'm assuming it's this: UP NEXT 18:00 Red Chip Money Report
and I'm watching live atm here: https://www.bloomberg.com/live/europe
Could all be false info so do share if you know better!
Yeah I saw that I just set my box to record Bloomberg from 5 to 7 pm just to be sure would of been better to state whether it was GMT or not
6pm Channel 502 under Teleshopping for some bizarre reason ??
Time could be 5pm in U.K. as Europe is 1 hour ahead
Don’t forget Dr Kunwar interview today Sunday at 6 pm
Friday 26 February, 2021
Tiziana Life Sciences Plc
Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with its CEO, Dr Kunwar Shailubhai, will air on The RedChip Money Report on Bloomberg Television on Saturday, February 27, 2021 at 7 p.m. local time across the United States and on the Bloomberg Network in Europe on Sunday, February 28, 2021 at 6 p.m. local time. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in 73M homes and on the Bloomberg Network in Europe in 100M homes at 6 p.m. local time on Sundays.
In the exclusive interview, Dr Shailubhai discusses topline data from Tiziana’s COVID-19 trial, its multiple Phase 2 trial launches expected in 2021, and the potential application of Foralumab in a wide range of autoimmune and inflammatory diseases.
“The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.